The APO-SYS team is the
extension of a 2006 Descartes Prize-winning consortium (“Apoptosis
mechanisms in cancer and AIDS” led by Guido Kroemer) that involves the
coordinator of the present consortium (Boris Zhivotovsky) as well as
four additional participants (Marja Jäättelä, Mauro Piacentini, Josef
Penninger and Klaus-Michael Debatin/Simone Fulda). This consortium has
now been extended to a total of 23 partners with the aim of uniting a
critical mass of investigators specialized in biology,
biomedicine/translational medicine, bioinformatics, biomathematics and
biostatistics that may solve important, disease-relevant problems by a
systems biology approach of apoptosis and other cell death programs.
Three of the partners involved in the theoretical part (Emmanuel
Barillot, Ralf Herwig/Hans Lehrach, Ron Shamir) were previously involved
in a common EC project on systems biology in FP6 ("European
Systems Biology Initiative for combating Complex Diseses") http://pybios.molgen.mpg.de/ESBIC-D),
led by Hans Lehrach. Furthermore, the APO-SYS consortium involves a
BioTech company that is specifically interested in systems biology
approaches applied to apoptosis-relevant diseases.
The
consortium will address the striking complexity of human cell death
pathways using an integrated method involving high-throughput screening,
and ”omics” approaches applied to biological systems and computational
modeling leading to accurate and disease relevant in silico
models of apoptotic signaling triggered along the two principal
pathways, the extrinsic pathways (stimulated by ligation of death
receptors) and the intrinsic pathways (stimulated by intracellular
stress causing mitochondrial membrane permeabilization). Furthermore,
the consortium will comparatively asses the system biology of
apoptotic and non-apoptotic cell death (necrosis, autophagy and
mitotic catastrophe) in order to understand the extent of overlap in
the mechanism leading to different phenotypic manifestation of cell
death as well as the molecular ”switches” that decide whether
cells remain alive or die through one or the other cell death pathway.
The research leading to these results has
received funding from the European Community's Seventh Framework
Programme (FP7/2007-2013) under grant agreement n° HEALTH-F4-2007-200767
for APO-SYS.